Adlai Nortye Ltd. (ANL)
NASDAQ: ANL · Real-Time Price · USD
12.17
-1.08 (-8.15%)
At close: Apr 28, 2026, 4:00 PM EDT
12.17
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:27 PM EDT
Adlai Nortye Revenue
In the year 2025, Adlai Nortye had annual revenue of $5.00M. Adlai Nortye had revenue of $5.00M in the half year ending December 31, 2025.
Revenue (ttm)
$5.00M
Revenue Growth
n/a
P/S Ratio
92.72
Revenue / Employee
$45,872
Employees
109
Market Cap
486.80M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CorMedix | 311.71M |
| Rigel Pharmaceuticals | 294.28M |
| Zevra Therapeutics | 106.47M |
| Prothena Corporation | 9.68M |
| Aclaris Therapeutics | 7.83M |
| Ocugen | 4.41M |
| Absci | 2.80M |
| Shattuck Labs | 1.00M |
ANL News
- 12 days ago - Adlai Nortye Announces $150.0 Million Private Placement Equity Financing - GlobeNewsWire
- 2 months ago - Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations - GlobeNewsWire
- 3 months ago - Adlai Nortye Announces $140.0 Million Private Placement Equity Financing - GlobeNewsWire
- 4 months ago - Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China - GlobeNewsWire
- 7 months ago - Adlai Nortye to Present Short Talk at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - GlobeNewsWire
- 2 years ago - Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024 - GlobeNewsWire
- 2 years ago - Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy - GlobeNewsWire
- 2 years ago - Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development - GlobeNewsWire